 |
|
|
REFERENCES
151.
Kasten GW, Martin ST: Successful cardiovascular
resuscitation after massive intravenous bupivacaine overdosage in anesthetized dogs.
Anesth Analg 64:491–497, 1985.
152.
Kasten GW, Martin ST: Bupivacaine cardiovascular
toxicity: Comparison of treatment with bretylium and lidocaine. Anesth Analg 64:911–916,
1985.
153.
Maxwell LG, Martin LD, Yaster M: Bupivacaine-induced
cardiac toxicity in neonates: Successful treatment with intravenous phenytoin.
Anesthesiology 80:682–686, 1994.
154.
Mather LE: Disposition of mepivacaine and bupivacaine
enantiomers in sheep. Br J Anaesth 67:239–246, 1991.
155.
Rutten AJ, Mather LE, McLean CF: Cardiovascular
effects and regional clearances of i.v. bupivacaine in sheep: Enantiomeric analysis.
Br J Anaesth 67:247–256, 1991.
156.
Bernards CM, Artu AA: Hexamethonium and midazolam
terminate dysrhythmias and hypertension caused by intracerebroventricular bupivacaine
in rabbits. Anesthesiology 74:89–96, 1991.
157.
Vanhoutte F, Vereecke J, Verbeke N, et al: Stereoselective
effects of the enantiomers of bupivacaine on the electrophysiological properties
of the guinea-pig papillary muscle. Br J Pharmacol 103:1275–1281, 1991.
158.
Lee-Son S, Wang GK, Concus A, et al: Stereoselective
inhibition of neuronal sodium channels by local anesthetics. Evidence for two sites
of action? Anesthesiology 77:324–335, 1992.
159.
Wang GK: Binding affinity and stereoselectivity
of local anesthetics in single batrachotoxin-activated Na+
channels.
J Gen Physiol 96:1105–1127, 1990.
160.
Arlock P: Actions of three local anaesthetics:
Lidocaine, bupivacaine and ropivacaine on guinea pig papillary muscle sodium channels
(Vmax). Pharmacol Toxicol 63:96–104, 1988.
161.
Pitkanen M, Feldman HS, Arthur GR, et al: Chronotropic
and inotropic effects of ropivacaine, bupivacaine, and lidocaine in the spontaneously
beating and electrically paced isolated, perfused rabbit heart. Reg Anesth 17:183–192,
1992.
162.
Moller R, Covino BG: Cardiac electrophysiologic
properties of bupivacaine and lidocaine compared with those of ropivacaine, a new
amide local anesthetic. Anesthesiology 72:322–329, 1990.
163.
Hickey R, Hoffman J, Ramamurthy S: A comparison
of ropivacaine 0.5% and bupivacaine 0.5% for brachial plexus block. Anesthesiology
74:639–642, 1991.
164.
Brown DL, Carpenter RL, Thompson GE: Comparison
of 0.5% ropivacaine and 0.5% bupivacaine for epidural anesthesia in patients undergoing
lower-extremity surgery. Anesthesiology 72:633–636, 1990.
165.
Kerkkamp HE, Gielen MJ, Edstrom HH: Comparison
of 0.75% ropivacaine with epinephrine and 0.75% bupivacaine with epinephrine in lumbar
epidural anesthesia. Reg Anesth 15:204–207, 1990.
166.
Katz JA, Knarr D, Bridenbaugh PO: A double-blind
comparison of 0.5% bupivacaine and 0.75% ropivacaine administered epidurally in humans.
Reg Anesth 15:250–252, 1990.
167.
Feldman HS, Covino BG: Comparative motor-blocking
effects of bupivacaine and ropivacaine, a new amino amide local anesthetic, in the
rat and dog. Anesth Analg 67:1047–1052, 1988.
168.
Nolte H, Fruhstorfer H, Edstrom HH: Local anesthetic
efficacy of ropivacaine (LEA 103) in ulnar nerve block. Reg Anesth 15:118–124,
1990.
169.
Kohane DS, Sankar WN, Shubina M, et al: Sciatic
nerve blockade in infant, adolescent, and adult rats: A comparison of ropivacaine
with bupivacaine. Anesthesiology 89:1199–1208, discussion 10A, 1998.
170.
Feldman HS, Arthur GR, Covino BG: Comparative
systemic toxicity of convulsant and supraconvulsant doses of intravenous ropivacaine,
bupivacaine, and lidocaine in the conscious dog. Anesth Analg 69:794–801,
1989.
171.
Rutten AJ, Nancarrow C, Mather LE, et al: Hemodynamic
and central nervous system effects of intravenous bolus doses of lidocaine, bupivacaine,
and ropivacaine in sheep. Anesth Analg 69:291–299, 1989.
172.
Lerman J, Nolan J, Eyres R, et al: Efficacy,
safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous
epidural infusion in children: A multicenter trial. Anesthesiology 99:1166–1174,
2003.
173.
Feldman HS, Arthur GR, Pitkanen M, et al: Treatment
of acute systemic toxicity after the rapid intravenous injection of ropivacaine and
bupivacaine in the conscious dog. Anesth Analg 73:373–384, 1991.
174.
Arthur GR, Feldman HS, Covino BG: Comparative
pharmacokinetics of bupivacaine and ropivacaine, a new amide local anesthetic. Anesth
Analg 67:1053–1058, 1988.
175.
Santos AC, Pedersen H, Harmon TW, et al: Does
pregnancy alter the systemic toxicity of local anesthetics? Anesthesiology 70:991–995,
1989.
176.
Sage DJ, Feldman HS, Arthur GR, et al: Influence
of lidocaine and bupivacaine on isolated guinea pig atria in the presence of acidosis
and hypoxia. Anesth Analg 63:1–7, 1984.
177.
Moore DC, Crawford RD, Scurlock JE: Severe hypoxia
and acidosis following local anesthetic-induced convulsions. Anesthesiology 53:259–260,
1980.
178.
Caplan RA, Ward RJ, Posner K, et al: Unexpected
cardiac arrest during spinal anesthesia: A closed claims analysis of predisposing
factors. Anesthesiology 68:5–11, 1988.
179.
Gelfin B, Shapiro L: Sinus bradycardia and asystole
during spinal and epidural anesthesia: A report of 13 cases. J Clin Anesth 10:278–285,
1998.
180.
Lund PC, Cwik JC: Propitocaine (Citanest) and
methemoglobinemia. Anesthesiology 26:569–571, 1965.
181.
Hjelm M, Holmdahl M: Biochemical effects of aromatic
amines. II. Cyanosis, methaemoglobinaemia and Heinzbody formation induced by a
local anaesthetic agent (prilocaine). Acta Anaesthesiol Scand 2:99–120, 1965.
182.
Taddio A, Stevens B, Craig K, et al: Efficacy
and safety of lidocaine-prilocaine cream for pain during circumcision. N Engl J
Med 336:1197–1201, 1997.
183.
Baluga JC, Casamayou R, Carozzi E, et al: Allergy
to local anaesthetics in dentistry. Myth or reality? Allergol Immunopathol 30:14–19,
2002.
184.
Sidhu SK, Shaw S, Wilkinson JD: A 19-year retrospective
study on benzocaine allergy in the United Kingdom. Am J Contact Dermat 10:57–61,
1999.
185.
Shojaei AR, Haas DA: Local anesthetic cartridges
and latex allergy: A literature review. J Can Dent Assoc 68:622–626, 2002.
186.
Norris MC, Honet JE, Leighton BL, et al: A comparison
of meperidine and lidocaine for spinal anesthesia for postpartum tubal ligation.
Reg Anesth 21:84–88, 1996.
187.
Rigler ML, Drasner K, Krejcie TC, et al: Cauda
equina syndrome after continuous spinal anesthesia. Anesth Analg 72:275–281,
1991.
188.
Lambert LA, Lambert DH, Strichartz GR: Irreversible
conduction block in isolated nerve by high concentrations of local anesthetics.
Anesthesiology 80:1082–1093, 1994.
189.
Bainton CR, Strichartz GR: Concentration dependence
of lidocaine-induced irreversible conduction loss in frog nerve. Anesthesiology
81:657–667, 1994.
190.
Adams HJ, Mastri AR, Eicholzer AW, et al: Morphologic
effects of intrathecal etidocaine and tetracaine on the rabbit spinal cord. Anesth
Analg 53:904–908, 1974.
191.
Ravindran RS, Bond VK, Tasch MD, et al: Prolonged
neural blockade following regional analgesia with 2-chloroprocaine. Anesth Analg
59:447–451, 1980.
192.
Reisner LS, Hochman BN, Plumer MH: Persistent
neurologic deficit and adhesive arachnoiditis following intrathecal 2-chloroprocaine
injection. Anesth Analg 59:452–454, 1980.
193.
Barsa J, Batra M, Fink BR, Sumi SM: A comparative
in vivo study of local neurotoxicity of lidocaine, bupivacaine, 2-chloroprocaine,
and a mixture of 2-chloroprocaine and bupivacaine. Anesth Analg 61:961–967,
1982.
194.
Rosen MA, Baysinger CL, Shnider SM, et al: Evaluation
of neurotoxicity after subarachnoid injection of large volumes of local anesthetic
solutions. Anesth Analg 62:802–808, 1983.
195.
Ravindran RS, Turner MS, Muller J: Neurologic
effects of subarachnoid administration of 2-chloroprocaine-CE, bupivacaine, and low
pH normal saline in dogs. Anesth Analg 61:279–283, 1982.
196.
Wang BC, Hillman DE, Spielholz NI, et al: Chronic
neurological deficits and Nesacaine-CE—an effect of the anesthetic, 2-chloroprocaine,
or the antioxidant, sodium bisulfite? Anesth Analg 63:445–447, 1984.
197.
Gissen A, Datta S, Lambert D: The chloroprocaine
controversy II. Is chloroprocaine neurotoxic? Reg Anesth 9:135, 1984.
198.
Taniguchi M, Bollen AW, Drasner K: Sodium bisulfite:
Scapegoat for chloroprocaine neurotoxicity? Anesthesiology 100:85–91, 2004.
199.
Freedman JM, Li DK, Drasner K, et al: Transient
neurologic symptoms after spinal anesthesia: An epidemiologic study of 1,863 patients
[erratum appears in Anesthesiology 1998 Dec;89(6):1614]. Anesthesiology 89:633–641,
1998.
200.
Hampl KF, Heinzmann-Wiedmer S, Luginbuehl I, et
al: Transient neurologic symptoms after spinal anesthesia: A lower incidence with
prilocaine and bupivacaine than with lidocaine. Anesthesiology 88:629–633,
1998.
201.
Pollock JE: Transient neurologic symptoms: Etiology,
risk factors, and management. Reg Anesth Pain Med 27:581–586, 2002.
202.
Zaric D, Christiansen C, Pace NL, Punjasawadwong
Y: Transient neurologic symptoms (TNS) following spinal anaesthesia with lidocaine
versus other local anaesthetics. Cochrane Database Syst Rev CD003006, 2003.
203.
Eberhart LH, Morin AM, Kranke P, et al: Transient
neurologic symptoms after spinal anesthesia. A quantitative systematic overview
(meta-analysis) of randomized controlled studies [in German]. Anaesthesist 51:539–546,
2002.
204.
Sakura S, Sumi M, Sakaguchi Y, et al: The addition
of phenylephrine contributes to the development of transient neurologic symptoms
after spinal anesthesia with 0.5% tetracaine. Anesthesiology 87:771–778, 1997.
205.
Sakura S, Bollen AW, Ciriales R, et al: Local
anesthetic neurotoxicity does not result from blockade of voltage-gated sodium channels.
Anesth Analg 81:338–346, 1995.
206.
Keld DB, Hein L, Dalgaard M, et al: The incidence
of transient neurologic symptoms (TNS) after spinal anaesthesia in patients undergoing
surgery in the supine position. Hyperbaric lidocaine 5% versus hyperbaric bupivacaine
0.5%. Acta Anaesthesiol Scand 44:285–290, 2000.
207.
Warner MA, Warner DO, Harper CM, et al: Lower
extremity neuropathies associated with lithotomy positions. Anesthesiology 93:938–942,
2000.
208.
Anema JG, Morey AF, McAninch JW, et al: Complications
related to the high lithotomy position during urethral reconstruction. J Urol 164:360–363,
2000.
209.
Libelius R, Sonesson B, Stamenovic BA, et al:
Denervation-like changes in skeletal muscle after treatment with a local anaesthetic
(Marchaine). J Anat 106:297–309, 1970.
210.
Benoit PW, Belt WD: Destruction and regeneration
of skeletal muscle after treatment with a local anaesthetic, bupivacaine (Marcaine).
J Anat 107:547–656, 1970.
211.
Benoit PW, Belt WD: Some effects of local anesthetic
agents on skeletal muscle. Exp Neurol 34:264–278, 1972.
212.
Denson DD, Raj PP, Saldahna F, et al: Continuous
perineural infusion of bupivacaine for prolonged analgesia: Pharmacokinetic considerations.
Int J Clin Pharmacol Ther Toxicol 21:591–597, 1983.
213.
Lund C, Mogensen T, Hjortso NC, et al: Systemic
morphine enhances spread of sensory analgesia during postoperative epidural bupivacaine
infusion. Lancet 2:1156–1157, 1985.
214.
Lee KC, Wilder RT, Smith RL, et al: Thermal hyperalgesia
accelerates and MK-801 prevents the development of tachyphylaxis to rat sciatic nerve
blockade. Anesthesiology 81:1284–1293, 1994.
215.
Sholas M, Wilder RT, Berde CB: Tachyphylaxis
to sciatic nerve blockade persists in spinalized rats [abstract]. Anesthesiology
81:A964, 1994.
216.
Wilder RT, Sholas MG, Berde CB: NG-nitro-L-arginine
methyl ester (L-NAME) prevents tachyphylaxis to local anesthetics in a dose-dependent
manner. Anesth Analg 83:1251–1255, 1996.
217.
Boogaerts JG, Lafont ND, Carlino S, et al: Biodistribution
of liposome-associated bupivacaine after extradural administration to rabbits. Br
J Anaesth 75:319–325, 1995.
218.
Mowat JJ, Mok MJ, MacLeod BA, et al: Liposomal
bupivacaine. Extended duration nerve blockade using large unilamellar vesicles that
exhibit a proton gradient. Anesthesiology 85:635–643, 1996.
219.
Kopacz DJ, Lacouture PG, Wu D, et al: The dose
response and effects of dexamethasone on bupivacaine microcapsules for intercostal
blockade (T9 to T11) in healthy volunteers. Anesth Analg 96:576–582, 2003.
220.
Curley J, Castillo J, Hotz J, et al: Prolonged
regional nerve blockade. Injectable biodegradable bupivacaine/polyester microspheres.
Anesthesiology 84:1401–1410, 1996.
221.
Kohane DS, Yieh J, Lu NT, et al: A re-examination
of tetrodotoxin for prolonged duration local anesthesia. Anesthesiology 89:119–131,
1998.
222.
Sudoh Y, Cahoon EE, Gerner P, et al: Tricyclic
antidepressants as long-acting local anesthetics. Pain 103:49–55, 2003.
